GC Genome Corporation (KOSDAQ:340450)
South Korea · Delayed Price · Currency is KRW 6,900.00
-100.00 (-1.43%)
Sep 18, 2026, 3:30 PM KST
GC Genome Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 163,190 | 161,298 | - | - | - | - | |
Market Cap Growth | -14.92% | - | - | - | - | - |
Enterprise Value | 124,912 | 124,035 | - | - | - | - |
Last Close Price | 6900.00 | 6820.00 | - | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 30.03 | 39.88 | - | - | - | - |
PS Ratio | 5.00 | 5.12 | - | - | - | - |
PB Ratio | 2.04 | 2.06 | - | - | - | - |
P/TBV Ratio | 2.06 | 2.08 | - | - | - | - |
P/FCF Ratio | 77.73 | 163.66 | - | - | - | - |
P/OCF Ratio | 54.52 | 124.37 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.83 | 3.93 | - | - | - | - |
EV/EBITDA Ratio | 26.28 | 30.23 | - | - | - | - |
EV/EBIT Ratio | 59.50 | 100.38 | - | - | - | - |
EV/FCF Ratio | 59.50 | 125.85 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.05 | 0.05 | 0.14 | 0.47 | 0.40 | 0.74 |
Debt / EBITDA Ratio | 0.90 | 0.98 | 2.35 | 3.18 | - | - |
Debt / FCF Ratio | 1.80 | 4.08 | 94.54 | - | - | - |
Net Debt / Equity Ratio | -0.48 | -0.46 | -0.06 | 0.13 | -0.26 | -0.61 |
Net Debt / EBITDA Ratio | -9.11 | -8.80 | -0.93 | 0.84 | 16.39 | 224.25 |
Net Debt / FCF Ratio | -18.23 | -36.63 | -37.60 | -0.77 | 1.25 | 3.96 |
Asset Turnover | 0.38 | 0.50 | 0.62 | 0.60 | 0.53 | 0.44 |
Inventory Turnover | 8.15 | 10.51 | 11.96 | 11.56 | 14.85 | - |
Quick Ratio | 11.20 | 17.67 | 3.74 | 1.00 | 2.13 | 6.26 |
Current Ratio | 11.82 | 18.59 | 4.27 | 1.12 | 2.32 | 6.42 |
Return on Equity (ROE) | 7.05% | 7.26% | -4.32% | -2.13% | -16.52% | 1.56% |
Return on Assets (ROA) | 1.13% | 1.23% | -1.85% | 0.22% | -4.43% | -3.13% |
Return on Invested Capital (ROIC) | 3.43% | 3.28% | -4.15% | 0.67% | -24.07% | -34.01% |
Return on Capital Employed (ROCE) | 1.90% | 1.50% | -3.30% | 0.50% | -8.40% | -5.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.32% | 2.51% | - | - | - | - |
FCF Yield | 1.29% | 0.61% | - | - | - | - |
Buyback Yield / Dilution | -22.05% | -20.29% | 0.66% | -13.53% | -0.97% | 10.25% |